{"ticker": {"uuid": "d29e2408-40e2-4614-bd83-b9dc7ff1218c", "symbol": "AVXL", "name": "Anavex Life Sciences Corp", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Anavex Life Sciences Submits Plan to Regain Compliance With Nasdaq Timely  Filing Rule", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/anavex-life-sciences-submits-plan-163149160.html", "source_name": "MT Newswires", "published_at": "2026-07-20T16:31:49+00:00", "published_display": "20 Jul 2026 16:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex Life Sciences submits compliance plan to Nasdaq after 10-Q delay", "summary": "Anavex Life Sciences (AVXL) submitted a Compliance Plan to Nasdaq following a late Form 10-Q filing for the quarter ended March 31, 2026. The company aims to regain compliance with Nasdaq Rule 5250(c)(1) and seek reinstatement of its listing. While the deficiency notice does not ", "url": "https://www.tradingview.com/news/tradingview:901858df66852:0-anavex-life-sciences-submits-compliance-plan-to-nasdaq-after-10-q-delay/", "source_name": "TradingView", "published_at": "2026-07-20T13:11:33", "published_display": "20 Jul 2026 13:11", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Anavex Life Sciences Corp. (AVXL) Investigation: Bronstein, Gewir", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Anavex Life Sciences Corp. (AVXL) securities. This investigation follows Anavex's withdrawal of its application for marketing authorization of blarcamesine in the EU, which caused the ", "url": "https://www.natlawreview.com/press-releases/anavex-life-sciences-corp-avxl-investigation-bronstein-gewirtz-grossman-1", "source_name": "The National Law Review", "published_at": "2026-07-01T09:39:38", "published_display": "01 Jul 2026 09:39", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex Life Sciences Corp.(NasdaqGS: AVXL) added to Russell 3000 Value Benchmark", "summary": "Anavex Life Sciences Corp. (NasdaqGS:AVXL) has been added to the Russell 3000 Value Benchmark. The company, a clinical-stage biopharmaceutical firm, focuses on developing treatments for central nervous system diseases using precision medicine, with pipeline products like ANAVEX 2", "url": "https://www.marketscreener.com/news/anavex-life-sciences-corp-nasdaqgs-avxl-added-to-russell-3000-value-benchmark-ce7f5fdcd088f125", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T20:41:19", "published_display": "29 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex: Waiting On Validation As Blarcamesine Shows Some Promise (NASDAQ:AVXL)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPMHJ3eVVxSEZtS0FLWjFhTGlySGpkQmJEQjdVOGtadmtDWlIyV0VZLXZxQjdqTUhCb25pSFYxMEVxNV9Gd0d4LXY3SUs2X3UxN0RueHY2ZFRfSENLUlNWNnkwY1J4X1NFMEtNemZWeXFiYTh1YkdNMV9kZnpyTHNHOEU2cHN2ZGtWdHdJTS1TRW1sMU5SSmV0S3lqQ0MxUmo3a0Z0am1vdw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Anavex Life Sciences Corp. Stocks", "summary": "This article lists various ETFs that include Anavex Life Sciences Corp. stocks in their portfolios. It details key metrics for each fund, such as market value, weight of Anavex in the ETF, issuer, management style, focus, expense ratio, AUM, price, change, and 3-year NAV total re", "url": "https://www.tradingview.com/symbols/LSE-0HFR/etfs/", "source_name": "TradingView", "published_at": "2026-06-29T03:41:30", "published_display": "29 Jun 2026 03:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Anavex Life Sciences Corp. \u2013 NASDAQ:AVXL", "summary": "This article provides a brief financial snippet for Anavex Life Sciences Corp. (NASDAQ: AVXL), specifically focusing on its forward price-to-sales ratio. It indicates the stock's market status as closed with no recent trades and includes standard disclaimer information from finan", "url": "https://www.tradingview.com/symbols/NASDAQ-AVXL/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T19:35:39", "published_display": "26 Jun 2026 19:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Anavex Life Sciences Corp. \u2013 NASDAQ:AVXL", "summary": "The article heading indicates a financial analysis of Anavex Life Sciences Corp. (NASDAQ: AVXL), specifically focusing on its enterprise value to revenue forward metric. The content itself, however, does not provide any specific financial data or analysis beyond the headline, mai", "url": "https://www.tradingview.com/symbols/NASDAQ-AVXL/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T10:10:55", "published_display": "26 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex Life Sciences sets Sept. 24, 2026 annual meeting; July 31 record date, Jul.10 proposal deadline", "summary": "Anavex Life Sciences (AVXL) has scheduled its 2026 Annual Meeting for September 24, 2026, with July 31, 2026, set as the record date for stockholders entitled to notice and vote. Due to the meeting being more than 30 days beyond the prior anniversary, the company has also announc", "url": "https://www.tradingview.com/news/tradingview:5b80d01a7fd3f:0-anavex-life-sciences-sets-sept-24-2026-annual-meeting-july-31-record-date-jul-10-proposal-deadline/", "source_name": "TradingView", "published_at": "2026-06-26T10:10:55", "published_display": "26 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex Life Sciences (NASDAQ: AVXL) schedules 2026 annual meeting and proposal deadlines", "summary": "Anavex Life Sciences Corp. has scheduled its 2026 Annual Meeting of Stockholders for September 24, 2026, setting July 31, 2026, as the record date for voting eligibility. Due to the meeting being held more than 30 days after the prior year's meeting, the company has updated the d", "url": "https://www.stocktitan.net/sec-filings/AVXL/8-k-anavex-life-sciences-corp-reports-material-event-e532313ce90b.html", "source_name": "Stock Titan", "published_at": "2026-06-26T10:10:55", "published_display": "26 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex Life Sciences Corp. Actuals & Estimates (BX:12X1)", "summary": "This article provides an overview of Anavex Life Sciences Corp. (BX:12X1), including its current stock price, market capitalization, and historical performance. It also details financial estimates, actual earnings, and an analyst forecast for the stock, emphasizing that the infor", "url": "https://www.tradingview.com/symbols/BX-12X1/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:39:55", "published_display": "26 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "12X1 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Anavex Life Sciences Corp. (12X1) stock for 2027 based on analyst opinions. It includes current stock price, market capitalization, historical price data, and financial information such as earnings and net income, noting that ", "url": "https://www.tradingview.com/symbols/BX-12X1/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T16:09:40", "published_display": "25 Jun 2026 16:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex Life Sciences Corp. Actuals & Estimates (FWB:12X1)", "summary": "This article provides financial actuals and estimates for Anavex Life Sciences Corp. (FWB:12X1), including analyst price targets, historical stock performance, and upcoming earnings dates. It highlights that analysts expect the stock's price to range between 17.20 EUR, and that t", "url": "https://www.tradingview.com/symbols/FWB-12X1/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T14:11:23", "published_display": "25 Jun 2026 14:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex Life Sciences Corp (AVXL) Institutional Confidence", "summary": "This article analyzes Anavex Life Sciences Corp's (AVXL) institutional confidence score, which stands at 3.00, placing it 193rd out of 389 in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 40.25%, a slight decrease quarter-over-quarter", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-avxl/sentiment", "source_name": "TradingKey", "published_at": "2026-06-24T03:11:32", "published_display": "24 Jun 2026 03:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex Life Sciences Corp (AVXL) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Anavex Life Sciences Corp (AVXL) has an earnings forecast score of 8.00, ranking 163rd in the Biotechnology & Medical Research industry. Analysts have a target price of $22.00, with a high of $24.00 and a low of $20.00, and a \"Buy\" rating for the stock. The company's previous qua", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-avxl/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T21:40:27", "published_display": "17 Jun 2026 21:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Top 5 Trending Stocks On Stocktwits Today: Webull, SharpLink, Anavex Life Sciences, BigBear.ai, And Oscar Health", "summary": "This article lists the top five trending stocks on Stocktwits, a social platform for investors, as of a recent trading day. The stocks highlighted are Webull, SharpLink Gaming Ltd., Anavex Life Sciences Corp., BigBear.ai Holdings Inc., and Oscar Health Inc., indicating which comp", "url": "https://www.msn.com/en-us/money/topstocks/top-5-trending-stocks-on-stocktwits-today-webull-sharplink-anavex-life-sciences-bigbearai-and-oscar-health/ar-AA1HQVW8?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-06-14T11:39:21", "published_display": "14 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AVXL Stock Chart | ANAVEX LIFE SCIENCES CORP (NASDAQ:AVXL)", "summary": "The article provides a stock chart for Anavex Life Sciences Corp (AVXL) on NASDAQ, detailing its current stock price, daily changes, and pre-market activity. It also lists various security sections available on ChartMill.com for AVXL, including technical analysis, fundamental ana", "url": "https://www.chartmill.com/stock/quote/AVXL/stock-chart", "source_name": "ChartMill", "published_at": "2026-06-05T11:10:51", "published_display": "05 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AVXL Technical Analysis & Stock Price Forecast", "summary": "The technical analysis for Anavex Life Sciences Corp (AVXL) indicates a \"Strong Sell\" consensus, aggregating 12 technical signals. Key indicators like MACD and several moving averages suggest bearish momentum, while the RSI is in a neutral range. The stock is trading below its 20", "url": "https://intellectia.ai/en/stock/AVXL/technical", "source_name": "Intellectia AI", "published_at": "2026-06-04T06:10:19", "published_display": "04 Jun 2026 06:10", "sentiment": "negative", "sentiment_pct": 28, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification", "summary": "Anavex Life Sciences (AVXL) has received an expected notification from Nasdaq regarding its delinquency in filing its quarterly report on Form 10-Q for the quarter ended March 31, 2026. This notification is a routine procedural matter and does not affect the company's listing or ", "url": "https://www.moomoo.com/news/post/70454385/anavex-life-sciences-receives-expected-nasdaq-delinquency-notification", "source_name": "Moomoo", "published_at": "2026-05-23T05:10:11", "published_display": "23 May 2026 05:10", "sentiment": "negative", "sentiment_pct": 19, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex Life Sciences receives Nasdaq delisting warning", "summary": "Anavex Life Sciences Corp. received a Nasdaq delisting warning for failing to timely file its Form 10-Q for the quarter ended March 31, 2026. The company has until July 20, 2026, to submit a compliance plan. Despite this, Anavex is actively developing therapies for central nervou", "url": "https://m.uk.investing.com/news/stock-market-news/anavex-life-sciences-receives-nasdaq-delisting-warning-93CH-4695123?ampMode=1", "source_name": "Investing.com UK", "published_at": "2026-05-22T17:40:18", "published_display": "22 May 2026 17:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex Life Sciences Corp. Receives Delinquency Notification From Nasdaq for Non-Compliance With Listing Rule", "summary": "Anavex Life Sciences Corp. announced it received a delinquency notification from Nasdaq because it has not yet filed its quarterly report on Form 10-Q for the period ended March 31, 2026. This notification indicates non-compliance with Nasdaq's continued listing requirements, spe", "url": "https://www.moomoo.com/news/post/70471945/anavex-life-sciences-corp-receives-delinquency-notification-from-nasdaq-for", "source_name": "Moomoo", "published_at": "2026-05-22T17:39:05", "published_display": "22 May 2026 17:39", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nasdaq warns Anavex (Nasdaq: AVXL) over delayed quarterly filing", "summary": "Anavex Life Sciences Corp. (AVXL) has received a delinquency notification from Nasdaq for failing to timely file its Form 10-Q for the quarter ended March 31, 2026. The company now has until July 20, 2026, to submit a plan to regain compliance, and potentially until November 16, ", "url": "https://www.stocktitan.net/sec-filings/AVXL/8-k-anavex-life-sciences-corp-reports-material-event-2847da5b4ca8.html", "source_name": "Stock Titan", "published_at": "2026-05-22T12:38:54", "published_display": "22 May 2026 12:38", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex Life Sciences Received Notice of Noncompliance", "summary": "Anavex Life Sciences (AVXL) received a notice of noncompliance from Nasdaq on May 20, 2026, for failing to timely file its Form 10-Q for the quarter ended March 31, 2026. The company's stock continues to trade on the Nasdaq Global Select Market, and it has until July 20, 2026, to", "url": "https://www.tradingview.com/news/tradingview:06db5a3d8b304:0-anavex-life-sciences-received-notice-of-noncompliance/", "source_name": "TradingView", "published_at": "2026-05-22T12:38:54", "published_display": "22 May 2026 12:38", "sentiment": "negative", "sentiment_pct": 26, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nasdaq flags Anavex for missing 10-Q, gives July 20 fix date", "summary": "Anavex Life Sciences (Nasdaq: AVXL) received a Nasdaq delinquency notification on May 20, 2026, for failing to timely file its Form 10-Q for the quarter ended March 31, 2026. The company has until July 20, 2026, to submit a compliance plan, and stated the notice does not immediat", "url": "https://www.stocktitan.net/news/AVXL/anavex-life-sciences-receives-expected-nasdaq-delinquency-4794btbk7atm.html", "source_name": "Stock Titan", "published_at": "2026-05-22T11:38:54", "published_display": "22 May 2026 11:38", "sentiment": "negative", "sentiment_pct": 37, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex Life Sciences Announces COO Departure Amid Restructuring", "summary": "Anavex Life Sciences announced the departure of its Chief Operating Officer, Felix Lauscher, on May 11, 2026, as part of a restructuring following the appointment of Dr. Terrie Kellmeyer as interim CEO. Lauscher, who served only since March 1, 2026, received a prorated salary and", "url": "https://www.theglobeandmail.com/investing/markets/stocks/AVXL/pressreleases/1979570/anavex-life-sciences-announces-coo-departure-amid-restructuring/", "source_name": "The Globe and Mail", "published_at": "2026-05-17T14:39:40", "published_display": "17 May 2026 14:39", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex (AVXL) COO exits amid reorganization; option grant largely forfeited", "summary": "Anavex Life Sciences Corp. announced the departure of its Chief Operating Officer, Felix Lauscher, effective May 11, 2026, as part of a reorganization following the appointment of an Interim CEO. Lauscher forfeited the majority of his 50,000 stock options, retaining only 4,167 ve", "url": "https://www.stocktitan.net/sec-filings/AVXL/8-k-anavex-life-sciences-corp-reports-material-event-621a4a966c52.html", "source_name": "Stock Titan", "published_at": "2026-05-15T20:40:00", "published_display": "15 May 2026 20:40", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Anavex (AVXL) interim CEO discloses detailed stock option grants", "summary": "Anavex Life Sciences' interim CEO, Terrie Kellmeyer, has filed an initial Form 3 detailing her stock option holdings. The filing reveals three grants of common stock options with varying exercise prices, expiration dates, and vesting schedules, including both time-based and perfo", "url": "https://www.stocktitan.net/sec-filings/AVXL/form-3-anavex-life-sciences-corp-initial-statement-of-beneficial-owne-7d5e16443ff1.html", "source_name": "Stock Titan", "published_at": "2026-05-14T20:10:35", "published_display": "14 May 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Anavex Life Sciences (NASDAQ: AVXL) delays 10-Q after CEO termination", "summary": "Anavex Life Sciences (NASDAQ: AVXL) has announced a delay in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2026. This delay is attributed to an ongoing independent Special Committee review following the termination of its previous CEO on April 30, 2026, ", "url": "https://www.stocktitan.net/sec-filings/AVXL/nt-10-q-anavex-life-sciences-corp-sec-filing-df9c7233fdd4.html", "source_name": "Stock Titan", "published_at": "2026-05-11T20:09:44", "published_display": "11 May 2026 20:09", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Anavex Life Sciences Names Interim CEO Amid Leadership Shift", "summary": "Anavex Life Sciences announced a leadership change, terminating CEO Christopher Missling for cause and appointing Terrie Kellmeyer as interim CEO. This transition, which also involves an extension to submit its quarterly report, places Kellmeyer in charge of advancing the company", "url": "https://www.theglobeandmail.com/investing/markets/stocks/AVXL/pressreleases/1768995/anavex-life-sciences-names-interim-ceo-amid-leadership-shift/", "source_name": "The Globe and Mail", "published_at": "2026-05-07T22:39:50", "published_display": "07 May 2026 22:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/anavex-life-sciences-board-directors-110000943.html", "source_name": "GlobeNewswire", "published_at": "2026-05-06T11:00:00+00:00", "published_display": "06 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQWFVDbVB4X2ktOUpMOFFwQ3YtN1RPV2lQU05qUEZWOWdlSldPQTBOemUxRHFVWlRISENudG13QXJ5UUlDaVJ0MkhTbzBhcTByNWJyMFA3OVRaMXRTckhkckdxdEhnWkYzU1VQTzZWRnVzZ20yYWU5czh3c2pDVnNGNkF5eXcxWnQxam1IR01XVlBvQzZjVUUwU0tYQnAxcEY1Q0k0aA?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright initiates Anavex Life Sciences stock with buy rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOUXQ5X3pHN2E5dHNhYU9SOFpEWUtBaVVrZTJHMFhEeEhqdGM2Q3lRVS16NWNnWG9yWE1CZnJ6ejlMU0xRaHhPUS1ySFJvZm10Z0ZYLVJmWkNUTDladlRUdURxaWp0cEpITG5LdzlON240M05DUmVsWjlFNG9hRE56UENGc3U5LWRLLUNzYnUzZ0RidGsxNWNQRHM3bUhxWFFHNXhiX1lBNFl1YjBybWlMM0NSMkxFeWlfSUhNTkhwNzkybzVl?oc=5", "source_name": "Investing.com", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Makes Anavex Life Sciences (AVXL) One of the Best Shorted Penny Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPU3B2RzF6VnlCVjBGYnBjYTY4ZGZFV09PWDdhek1aaER6WFRIRDRqUmk4di1FV2JHaUlFZ0szSGJfQ2Q0VG1WNUc4bGNDSG9vY3ZSSEtzVWpwdjFXaUZ5YUQ3NVBUVmhZcjA2QjFoOWduZlpBM1cwdjZUN0o0TmlabjFxVktfYUtMWTNqancwYXd3RGZiZDRSYkVZbkRIMUF4VHc?oc=5", "source_name": "Market source", "published_at": "2026-04-26T07:00:00+00:00", "published_display": "26 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Anavex Life Sciences Corp. (AVXL) Stock Analysis: Exploring The 547% Potential Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNbjNRWVBlcmVyWDNWck43aWJkT1VKUGRCSHd2eV9vSENGTnZmcDhiVFVDRDRJM1RHV2lGaHdWTXlab1J3ZTdnaVhVeXNyRHhPMklvQW1lN1pzczV1SGVRd0xYNEZLZXRvWFJqY3VNekgtN1QwUEROdHBsek1uVm8xVHh5d2JNdW1vYXZ5VkR2eTh1NFZzbVFKY2dpc05zRDNwSnRiNnhmcEduSkhVZ3NJUXBoYkxHb2NOODZqbVJMWGtuRVlaWUk1bTh1MA?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex CEO Christopher Missling speaks April 14 at Needham", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPOGcteE9ndmJBQVFZSDFOUFRWeHExU1Y0bVpJV2NydzRHUFVpaTJ0RkRHV0V6cURJMjlIS25mQ1F5OEpUcEppLVBlaldRcW5iZGx0SDBDWHBYRm03dFFoU3ItWjdDREVvZHhqc0FQUThIZUVVM1VOb0RvT29pbHVBQXFmNWtRNTZrRGNYTWE4WWlrQWZtcEppWTNZSjNpclowNmZVemR6WmNaLVh4YVU2Zlg5SE1oNmx3SnM3M3dn?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex Life Sciences Corp. (AVXL) Stock Analysis: Exploring a Potential 635% Upside in Biotechnology", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxPMERVRnVOY1JzQ3hHX2VRT05VRDh1ODZfU3RMOXhuOWwwR1M0WC0tenQxREljMjZSOWZ5SEVsQVY3TTVNMEN5cXEzTjNuLXBwRVF4bFMxbEQ4WVBCN3dUSTc0UmRhTUdtSmlQZnhCZlVfLU9yVEFjQjlYc0RTaUFvM3VjTU53QTh5Rk9HSFFiYjNmdVZVc1g5Y0J0d21GVzhyX05GMVRLR19wYk9uTGZMYzEzaEhyTUtUZGZYMy0yaXhiQ2F1MkEtaGYwbzZXMGtKdGRCazJQdzhsbC1TcWxZ?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-04-03T07:00:00+00:00", "published_display": "03 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After withdrawing its EU filing, Anavex keeps Alzheimer\u2019s drug in talks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNVlNNc28zTmxSd3JnQXZGTUtrS0lrRTliZkRtQ3prbmk0MUNFOTIxQmYyeEFydWxxMzYwcEVsdkJRQ3dCTEZQSFRkeDBqOUgxVENfTkJkdUJCc0ZnRVppTENScE9VWHI3VTNtcUc4QkxMaTVzbkptV083bC1HZXlQbjhmaUloRUFpLVpISDRpNUpOSllLdWg2eWhpZW5MeEJ0NnNHNl9YWHItajh2aVE?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Anavex Life Sciences Stock Is Deeply Oversold. Should You Buy the Dip?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNTWI2Q3FPazVRbkRULXJaa2pXNlpzcEE5VV8tbUVlbkJOYkZRZUVQa0VJbWZqZTZuUmJKdnYzSk5wQnh5RnVRSmlRcElGNGtsZ19zN2ZVR3duRnJ3cjd4SnVfTmRXckluYS00VnZxbmdwdGdid1NUODJPbXdsd0dydFhFMWVZcUFmWkpLZHVSLU44Tkl5OENUaVZ3U212Z1U?oc=5", "source_name": "Market source", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxPQXpoZERCMDl6d3pQR2RZMjBlM180bENuVHdfRHNNZWdVMUljSUJfM3ZKMEFFTXF4S1YtWkQ2cXRHakN1UXRVNms5R0MwcG5zWEd2LTVCc1N0LWVMUXFiWFhfc085b3ZKZGNmTk5jOHlsXzZvYW5paHU3ZDd0dVU5MVRGMVR2OUhORWZfNjEyZm4?oc=5", "source_name": "Market source", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AVXL Stock Tanks After Anavex Withdraws EU Bid For Alzheimer's Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNYzF0OUtRRU9WaWR3d3FXZS0zVGZGTDhTRHphak10ZUFFM2lzel91M1czN2M4X0VwbFlndWxidXN0b05fOFNmZGxPT0R0UWE2YzdzU2lzVXE2RW02eGZMRGxZbjk5TzlJdVpTRzdhOUdCV3VPdDRYX0hFR3MwVlIyVzRPbVVlb2g4aU1FclZSZ3UyZERERzc5bzNRYkpwMmI3RlB2Z3g5UWh4cklhMnpUWkxKMG9zRG9IcXd0S3VwVF85cVAwbTZUdQ?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EU review halts Anavex\u2019s Alzheimer\u2019s drug bid, more data next", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOM05XTEZ5SUdybTk1MUp2eXZlX21CY2xUOEpGRVhJblNjN3NPdlZHZFFaWXBZdTFmV1MyNVlDUER3VklKSExpR0w1VEN4NkNDTGNtclFzNHNqN1JPN0M4bHQ3NWVjRHlaQ0RTeURZMU44ZmU3ckJ2eTF2WmtHMjhzYzNRVEhvUnhiSXFkQ0d0Vlk4SEpfTGc3d2wzSzJWY1NTeTBRaV9kaDJHQ3dEU0pueWFGOXk0RW1HYm9rV2Fxaw?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AVXL Stock Soars After Anavex\u2019s New Data Suggests Its Alzheimer\u2019s Drug May Slow Brain Shrinkage", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxNdTNrODBQd21DX3lDVjJXeXdWYmJpeG1FZ0ZLS3YxbWs4OUlfazZtZ3lwcm0xS3UwbVBVdzBxQVpNWWt1XzluZ1ZDcW9aNTByNjQwbS1XckRnYjB5ZWU4bmdaNXBXVk5lcWwwS3VpQWVhb3hlN0tDOHVBT01aN3NZV01ya25peDRMT0Uyc25hU3NxbkViamlwQXU3VXRmZlJBc1ZlZXFGaENTSmx5MFVGOGJHTzBUdHZ0ODBHWDBLSEdJcU5aZmVrUFQyUjRDWVpFdnVoTg?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex Life Sciences Stock Rises After Experimental Alzheimer\u2019s Drug Slows Cognitive Decline In Study", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxPVEQxZVJCaFp2NVJOTWF6N0gtam9Ha01uRThjNkhpeEtaTTZ2ZnBXYlFDYlJSLVRvS012NWxkUEd0MWZlVVo4ZlNQVDhycTAzdFoxMzhrV1lBM3o1SXFmczhfSEEtenk2WXZ1bnhORGlyLWFQUnpQdF94bUlVcUpQRlZNbjkzQ082QTBTNExEUl9uWlBLeGVidlI4Q1dEbzN1RndWRzhfbTNHT2UtVlEwS0NDT21yNDRHcUpTY2MySVR4NFJNWHB2WV9iT1BJeWp0Qk0ta0F5VFpRVVJDRUloeUUzekFLMm9nTUpZ?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex Life Sciences (AVXL) Upgraded to Buy: Here's What You Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxONmVOdXVCVEtTZ01LUEY0b0lCMGZLWDhvby05TWFPTkViSVRSSjVXbzdDa3c4Um5qRXZiS1VkSEx5dFRFNGZHVjhQWXZSaWRyVVlTMTlsU25IUnNROENSajRwSWZERDc1UmxPSnZ1TVZTUnYwMEY5T1dackRWV1pxSG1LYmZCOWs?oc=5", "source_name": "Market source", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Anavex Life Sciences (AVXL) Stock Outpacing Its Medical Peers This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxPSW43b2tQQ2lzdGtSeUdkbnNwcWtZLXdqSEpVOUxONTRXYjBuTzJxMV9uUFR4ZWdRcXZfWk9vX2VMNmZNejZhR2FxajBTZTUwZ2x0OFk0ZU9EYk5RZ19mazhNNkQ3SkNaOUFqWjJkLUhxUzZnM2lLNm80Rm93ZThwai1Obw?oc=5", "source_name": "Market source", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex Life Sciences Corp. Common Stock (AVXL) Stock Price Today: $2.43", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE1wakkxRmRmSzNfTWpfQ0NUdExIQXY5TVJPME5MZmRJT2lUSk4weTRoUEpHeHJic2E3aFFvMGZtUmZkRnlGazRUaVBhMHlGTUVfRUhDalBwWQ?oc=5", "source_name": "Gotrade", "published_at": "2026-02-02T07:11:00+00:00", "published_display": "02 Feb 2026 07:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Down 50.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Anavex Life Sciences (AVXL)", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTFAwUzNGOG1XWm05LW9ZbDJ1MV9MUUg5YlV1WGFCOWRpQmFqNmZpbTJ2eFNROVpzY3pjcTFBU1RLSml3NUhEeVc5QWM2Vy10RERDS1ZyZi05QTM0X1JacnZsZU1CSjB6eURoZW1jNWZQU0g?oc=5", "source_name": "Market source", "published_at": "2025-12-02T08:00:00+00:00", "published_display": "02 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPdkZmb1BmZWU1WUY3UFh4QkNFdzMxc19LWEhpMzdWZlh5eWJjTDJGcmF2SS0wVnV0ZlVRMmRTSUdhaDlDR0ZEY3BRY1AwYkV5TU1QVVJXalpzeFlVVTdteXk2YWdaMVJqU0J0YkxXOGRrSmlKdWlOV3gxQlFtM0M0QUp6UjRQcGxrcTRia2J5bFB5RHczNnktNTVkblhwYWhHZFdBbWZWQTVkXzhSZVh0VGFkdWtDTFBfbHNQUlFaRXZjTlByQWc?oc=5", "source_name": "Anavex Life Sciences", "published_at": "2025-11-25T08:00:00+00:00", "published_display": "25 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Anavex Life Sciences (AVXL) Is Down After an EMA Setback for Its Alzheimer\u2019s Drug Application", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-16T08:00:00+00:00", "published_display": "16 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AVXL Stock Price and Chart \u2014 NASDAQ:AVXL", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE50N29nWllNbmlzNmFmZHItd3VJZkNYZjZZaWljR1lRTzFReHV3WWl4OGQ1U3RsLXpNbTlhVTJ6bUpEVDFkWjd5dG9vQ0F0WllpYlM4aDRVWXg0ZHhC?oc=5", "source_name": "TradingView", "published_at": "2025-10-29T07:00:00+00:00", "published_display": "29 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex Life Sciences Stock Falls After Hours On $300M Raise Plan; Retail Traders Think It\u2019s A \u2018Smart\u2019 Move", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-wFBVV95cUxPejlmR0ViX1VNSmd1V2w0a1RvZm5CYUpKYUFrYmRHS1ZBNHc4RktvWURrdzlQZTQwd0daWUZpRHpsclpreURhYV8zNjJtRk9taTNWOFFiUkMzb1htdHpzYzZTb1hFc2NxY3g2RWRCMXJMZjJlaW5Xak9EdEwxTHh5dTdWTm5QaDZ5SkRhTVR5NTZvSHdvZDhSdWw2R1kzOGFKRE5nYW9qYmM2cUhhR1JiUWtTM0hGUm9QaUppN3FDVngyTGEyaHFqMG00OFN4NkNWZGNEWWhoOGVQVU9maWRPendWZjNFNEdKUXBaNG1NYmNLWnFObkpHR3lGVQ?oc=5", "source_name": "Stocktwits", "published_at": "2025-07-14T07:00:00+00:00", "published_display": "14 Jul 2025 07:00", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Anavex Life Sciences Submits Plan to Regain Compliance With Nasdaq Timely  Filing Rule", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/anavex-life-sciences-submits-plan-163149160.html", "source_name": "MT Newswires", "published_at": "2026-07-20T16:31:49+00:00", "published_display": "20 Jul 2026 16:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex Life Sciences submits compliance plan to Nasdaq after 10-Q delay", "summary": "Anavex Life Sciences (AVXL) submitted a Compliance Plan to Nasdaq following a late Form 10-Q filing for the quarter ended March 31, 2026. The company aims to regain compliance with Nasdaq Rule 5250(c)(1) and seek reinstatement of its listing. While the deficiency notice does not ", "url": "https://www.tradingview.com/news/tradingview:901858df66852:0-anavex-life-sciences-submits-compliance-plan-to-nasdaq-after-10-q-delay/", "source_name": "TradingView", "published_at": "2026-07-20T13:11:33", "published_display": "20 Jul 2026 13:11", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex Life Sciences Corp. (AVXL) Investigation: Bronstein, Gewir", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Anavex Life Sciences Corp. (AVXL) securities. This investigation follows Anavex's withdrawal of its application for marketing authorization of blarcamesine in the EU, which caused the ", "url": "https://www.natlawreview.com/press-releases/anavex-life-sciences-corp-avxl-investigation-bronstein-gewirtz-grossman-1", "source_name": "The National Law Review", "published_at": "2026-07-01T09:39:38", "published_display": "01 Jul 2026 09:39", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex Life Sciences Corp.(NasdaqGS: AVXL) added to Russell 3000 Value Benchmark", "summary": "Anavex Life Sciences Corp. (NasdaqGS:AVXL) has been added to the Russell 3000 Value Benchmark. The company, a clinical-stage biopharmaceutical firm, focuses on developing treatments for central nervous system diseases using precision medicine, with pipeline products like ANAVEX 2", "url": "https://www.marketscreener.com/news/anavex-life-sciences-corp-nasdaqgs-avxl-added-to-russell-3000-value-benchmark-ce7f5fdcd088f125", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T20:41:19", "published_display": "29 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex: Waiting On Validation As Blarcamesine Shows Some Promise (NASDAQ:AVXL)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPMHJ3eVVxSEZtS0FLWjFhTGlySGpkQmJEQjdVOGtadmtDWlIyV0VZLXZxQjdqTUhCb25pSFYxMEVxNV9Gd0d4LXY3SUs2X3UxN0RueHY2ZFRfSENLUlNWNnkwY1J4X1NFMEtNemZWeXFiYTh1YkdNMV9kZnpyTHNHOEU2cHN2ZGtWdHdJTS1TRW1sMU5SSmV0S3lqQ0MxUmo3a0Z0am1vdw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Anavex Life Sciences Corp. Stocks", "summary": "This article lists various ETFs that include Anavex Life Sciences Corp. stocks in their portfolios. It details key metrics for each fund, such as market value, weight of Anavex in the ETF, issuer, management style, focus, expense ratio, AUM, price, change, and 3-year NAV total re", "url": "https://www.tradingview.com/symbols/LSE-0HFR/etfs/", "source_name": "TradingView", "published_at": "2026-06-29T03:41:30", "published_display": "29 Jun 2026 03:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Anavex Life Sciences Corp. \u2013 NASDAQ:AVXL", "summary": "This article provides a brief financial snippet for Anavex Life Sciences Corp. (NASDAQ: AVXL), specifically focusing on its forward price-to-sales ratio. It indicates the stock's market status as closed with no recent trades and includes standard disclaimer information from finan", "url": "https://www.tradingview.com/symbols/NASDAQ-AVXL/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T19:35:39", "published_display": "26 Jun 2026 19:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Anavex Life Sciences Corp. \u2013 NASDAQ:AVXL", "summary": "The article heading indicates a financial analysis of Anavex Life Sciences Corp. (NASDAQ: AVXL), specifically focusing on its enterprise value to revenue forward metric. The content itself, however, does not provide any specific financial data or analysis beyond the headline, mai", "url": "https://www.tradingview.com/symbols/NASDAQ-AVXL/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T10:10:55", "published_display": "26 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex Life Sciences sets Sept. 24, 2026 annual meeting; July 31 record date, Jul.10 proposal deadline", "summary": "Anavex Life Sciences (AVXL) has scheduled its 2026 Annual Meeting for September 24, 2026, with July 31, 2026, set as the record date for stockholders entitled to notice and vote. Due to the meeting being more than 30 days beyond the prior anniversary, the company has also announc", "url": "https://www.tradingview.com/news/tradingview:5b80d01a7fd3f:0-anavex-life-sciences-sets-sept-24-2026-annual-meeting-july-31-record-date-jul-10-proposal-deadline/", "source_name": "TradingView", "published_at": "2026-06-26T10:10:55", "published_display": "26 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex Life Sciences (NASDAQ: AVXL) schedules 2026 annual meeting and proposal deadlines", "summary": "Anavex Life Sciences Corp. has scheduled its 2026 Annual Meeting of Stockholders for September 24, 2026, setting July 31, 2026, as the record date for voting eligibility. Due to the meeting being held more than 30 days after the prior year's meeting, the company has updated the d", "url": "https://www.stocktitan.net/sec-filings/AVXL/8-k-anavex-life-sciences-corp-reports-material-event-e532313ce90b.html", "source_name": "Stock Titan", "published_at": "2026-06-26T10:10:55", "published_display": "26 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex Life Sciences Corp. Actuals & Estimates (BX:12X1)", "summary": "This article provides an overview of Anavex Life Sciences Corp. (BX:12X1), including its current stock price, market capitalization, and historical performance. It also details financial estimates, actual earnings, and an analyst forecast for the stock, emphasizing that the infor", "url": "https://www.tradingview.com/symbols/BX-12X1/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:39:55", "published_display": "26 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "12X1 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Anavex Life Sciences Corp. (12X1) stock for 2027 based on analyst opinions. It includes current stock price, market capitalization, historical price data, and financial information such as earnings and net income, noting that ", "url": "https://www.tradingview.com/symbols/BX-12X1/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T16:09:40", "published_display": "25 Jun 2026 16:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex Life Sciences Corp. Actuals & Estimates (FWB:12X1)", "summary": "This article provides financial actuals and estimates for Anavex Life Sciences Corp. (FWB:12X1), including analyst price targets, historical stock performance, and upcoming earnings dates. It highlights that analysts expect the stock's price to range between 17.20 EUR, and that t", "url": "https://www.tradingview.com/symbols/FWB-12X1/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T14:11:23", "published_display": "25 Jun 2026 14:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex Life Sciences Corp (AVXL) Institutional Confidence", "summary": "This article analyzes Anavex Life Sciences Corp's (AVXL) institutional confidence score, which stands at 3.00, placing it 193rd out of 389 in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 40.25%, a slight decrease quarter-over-quarter", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-avxl/sentiment", "source_name": "TradingKey", "published_at": "2026-06-24T03:11:32", "published_display": "24 Jun 2026 03:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex Life Sciences Corp (AVXL) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Anavex Life Sciences Corp (AVXL) has an earnings forecast score of 8.00, ranking 163rd in the Biotechnology & Medical Research industry. Analysts have a target price of $22.00, with a high of $24.00 and a low of $20.00, and a \"Buy\" rating for the stock. The company's previous qua", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-avxl/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T21:40:27", "published_display": "17 Jun 2026 21:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Top 5 Trending Stocks On Stocktwits Today: Webull, SharpLink, Anavex Life Sciences, BigBear.ai, And Oscar Health", "summary": "This article lists the top five trending stocks on Stocktwits, a social platform for investors, as of a recent trading day. The stocks highlighted are Webull, SharpLink Gaming Ltd., Anavex Life Sciences Corp., BigBear.ai Holdings Inc., and Oscar Health Inc., indicating which comp", "url": "https://www.msn.com/en-us/money/topstocks/top-5-trending-stocks-on-stocktwits-today-webull-sharplink-anavex-life-sciences-bigbearai-and-oscar-health/ar-AA1HQVW8?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-06-14T11:39:21", "published_display": "14 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AVXL Stock Chart | ANAVEX LIFE SCIENCES CORP (NASDAQ:AVXL)", "summary": "The article provides a stock chart for Anavex Life Sciences Corp (AVXL) on NASDAQ, detailing its current stock price, daily changes, and pre-market activity. It also lists various security sections available on ChartMill.com for AVXL, including technical analysis, fundamental ana", "url": "https://www.chartmill.com/stock/quote/AVXL/stock-chart", "source_name": "ChartMill", "published_at": "2026-06-05T11:10:51", "published_display": "05 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AVXL Technical Analysis & Stock Price Forecast", "summary": "The technical analysis for Anavex Life Sciences Corp (AVXL) indicates a \"Strong Sell\" consensus, aggregating 12 technical signals. Key indicators like MACD and several moving averages suggest bearish momentum, while the RSI is in a neutral range. The stock is trading below its 20", "url": "https://intellectia.ai/en/stock/AVXL/technical", "source_name": "Intellectia AI", "published_at": "2026-06-04T06:10:19", "published_display": "04 Jun 2026 06:10", "sentiment": "negative", "sentiment_pct": 28, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification", "summary": "Anavex Life Sciences (AVXL) has received an expected notification from Nasdaq regarding its delinquency in filing its quarterly report on Form 10-Q for the quarter ended March 31, 2026. This notification is a routine procedural matter and does not affect the company's listing or ", "url": "https://www.moomoo.com/news/post/70454385/anavex-life-sciences-receives-expected-nasdaq-delinquency-notification", "source_name": "Moomoo", "published_at": "2026-05-23T05:10:11", "published_display": "23 May 2026 05:10", "sentiment": "negative", "sentiment_pct": 19, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex Life Sciences receives Nasdaq delisting warning", "summary": "Anavex Life Sciences Corp. received a Nasdaq delisting warning for failing to timely file its Form 10-Q for the quarter ended March 31, 2026. The company has until July 20, 2026, to submit a compliance plan. Despite this, Anavex is actively developing therapies for central nervou", "url": "https://m.uk.investing.com/news/stock-market-news/anavex-life-sciences-receives-nasdaq-delisting-warning-93CH-4695123?ampMode=1", "source_name": "Investing.com UK", "published_at": "2026-05-22T17:40:18", "published_display": "22 May 2026 17:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex Life Sciences Corp. Receives Delinquency Notification From Nasdaq for Non-Compliance With Listing Rule", "summary": "Anavex Life Sciences Corp. announced it received a delinquency notification from Nasdaq because it has not yet filed its quarterly report on Form 10-Q for the period ended March 31, 2026. This notification indicates non-compliance with Nasdaq's continued listing requirements, spe", "url": "https://www.moomoo.com/news/post/70471945/anavex-life-sciences-corp-receives-delinquency-notification-from-nasdaq-for", "source_name": "Moomoo", "published_at": "2026-05-22T17:39:05", "published_display": "22 May 2026 17:39", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nasdaq warns Anavex (Nasdaq: AVXL) over delayed quarterly filing", "summary": "Anavex Life Sciences Corp. (AVXL) has received a delinquency notification from Nasdaq for failing to timely file its Form 10-Q for the quarter ended March 31, 2026. The company now has until July 20, 2026, to submit a plan to regain compliance, and potentially until November 16, ", "url": "https://www.stocktitan.net/sec-filings/AVXL/8-k-anavex-life-sciences-corp-reports-material-event-2847da5b4ca8.html", "source_name": "Stock Titan", "published_at": "2026-05-22T12:38:54", "published_display": "22 May 2026 12:38", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex Life Sciences Received Notice of Noncompliance", "summary": "Anavex Life Sciences (AVXL) received a notice of noncompliance from Nasdaq on May 20, 2026, for failing to timely file its Form 10-Q for the quarter ended March 31, 2026. The company's stock continues to trade on the Nasdaq Global Select Market, and it has until July 20, 2026, to", "url": "https://www.tradingview.com/news/tradingview:06db5a3d8b304:0-anavex-life-sciences-received-notice-of-noncompliance/", "source_name": "TradingView", "published_at": "2026-05-22T12:38:54", "published_display": "22 May 2026 12:38", "sentiment": "negative", "sentiment_pct": 26, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nasdaq flags Anavex for missing 10-Q, gives July 20 fix date", "summary": "Anavex Life Sciences (Nasdaq: AVXL) received a Nasdaq delinquency notification on May 20, 2026, for failing to timely file its Form 10-Q for the quarter ended March 31, 2026. The company has until July 20, 2026, to submit a compliance plan, and stated the notice does not immediat", "url": "https://www.stocktitan.net/news/AVXL/anavex-life-sciences-receives-expected-nasdaq-delinquency-4794btbk7atm.html", "source_name": "Stock Titan", "published_at": "2026-05-22T11:38:54", "published_display": "22 May 2026 11:38", "sentiment": "negative", "sentiment_pct": 37, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex Life Sciences Announces COO Departure Amid Restructuring", "summary": "Anavex Life Sciences announced the departure of its Chief Operating Officer, Felix Lauscher, on May 11, 2026, as part of a restructuring following the appointment of Dr. Terrie Kellmeyer as interim CEO. Lauscher, who served only since March 1, 2026, received a prorated salary and", "url": "https://www.theglobeandmail.com/investing/markets/stocks/AVXL/pressreleases/1979570/anavex-life-sciences-announces-coo-departure-amid-restructuring/", "source_name": "The Globe and Mail", "published_at": "2026-05-17T14:39:40", "published_display": "17 May 2026 14:39", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex (AVXL) COO exits amid reorganization; option grant largely forfeited", "summary": "Anavex Life Sciences Corp. announced the departure of its Chief Operating Officer, Felix Lauscher, effective May 11, 2026, as part of a reorganization following the appointment of an Interim CEO. Lauscher forfeited the majority of his 50,000 stock options, retaining only 4,167 ve", "url": "https://www.stocktitan.net/sec-filings/AVXL/8-k-anavex-life-sciences-corp-reports-material-event-621a4a966c52.html", "source_name": "Stock Titan", "published_at": "2026-05-15T20:40:00", "published_display": "15 May 2026 20:40", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex (AVXL) interim CEO discloses detailed stock option grants", "summary": "Anavex Life Sciences' interim CEO, Terrie Kellmeyer, has filed an initial Form 3 detailing her stock option holdings. The filing reveals three grants of common stock options with varying exercise prices, expiration dates, and vesting schedules, including both time-based and perfo", "url": "https://www.stocktitan.net/sec-filings/AVXL/form-3-anavex-life-sciences-corp-initial-statement-of-beneficial-owne-7d5e16443ff1.html", "source_name": "Stock Titan", "published_at": "2026-05-14T20:10:35", "published_display": "14 May 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex Life Sciences (NASDAQ: AVXL) delays 10-Q after CEO termination", "summary": "Anavex Life Sciences (NASDAQ: AVXL) has announced a delay in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2026. This delay is attributed to an ongoing independent Special Committee review following the termination of its previous CEO on April 30, 2026, ", "url": "https://www.stocktitan.net/sec-filings/AVXL/nt-10-q-anavex-life-sciences-corp-sec-filing-df9c7233fdd4.html", "source_name": "Stock Titan", "published_at": "2026-05-11T20:09:44", "published_display": "11 May 2026 20:09", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex Life Sciences Names Interim CEO Amid Leadership Shift", "summary": "Anavex Life Sciences announced a leadership change, terminating CEO Christopher Missling for cause and appointing Terrie Kellmeyer as interim CEO. This transition, which also involves an extension to submit its quarterly report, places Kellmeyer in charge of advancing the company", "url": "https://www.theglobeandmail.com/investing/markets/stocks/AVXL/pressreleases/1768995/anavex-life-sciences-names-interim-ceo-amid-leadership-shift/", "source_name": "The Globe and Mail", "published_at": "2026-05-07T22:39:50", "published_display": "07 May 2026 22:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/anavex-life-sciences-board-directors-110000943.html", "source_name": "GlobeNewswire", "published_at": "2026-05-06T11:00:00+00:00", "published_display": "06 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQWFVDbVB4X2ktOUpMOFFwQ3YtN1RPV2lQU05qUEZWOWdlSldPQTBOemUxRHFVWlRISENudG13QXJ5UUlDaVJ0MkhTbzBhcTByNWJyMFA3OVRaMXRTckhkckdxdEhnWkYzU1VQTzZWRnVzZ20yYWU5czh3c2pDVnNGNkF5eXcxWnQxam1IR01XVlBvQzZjVUUwU0tYQnAxcEY1Q0k0aA?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright initiates Anavex Life Sciences stock with buy rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOUXQ5X3pHN2E5dHNhYU9SOFpEWUtBaVVrZTJHMFhEeEhqdGM2Q3lRVS16NWNnWG9yWE1CZnJ6ejlMU0xRaHhPUS1ySFJvZm10Z0ZYLVJmWkNUTDladlRUdURxaWp0cEpITG5LdzlON240M05DUmVsWjlFNG9hRE56UENGc3U5LWRLLUNzYnUzZ0RidGsxNWNQRHM3bUhxWFFHNXhiX1lBNFl1YjBybWlMM0NSMkxFeWlfSUhNTkhwNzkybzVl?oc=5", "source_name": "Investing.com", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Makes Anavex Life Sciences (AVXL) One of the Best Shorted Penny Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPU3B2RzF6VnlCVjBGYnBjYTY4ZGZFV09PWDdhek1aaER6WFRIRDRqUmk4di1FV2JHaUlFZ0szSGJfQ2Q0VG1WNUc4bGNDSG9vY3ZSSEtzVWpwdjFXaUZ5YUQ3NVBUVmhZcjA2QjFoOWduZlpBM1cwdjZUN0o0TmlabjFxVktfYUtMWTNqancwYXd3RGZiZDRSYkVZbkRIMUF4VHc?oc=5", "source_name": "Market source", "published_at": "2026-04-26T07:00:00+00:00", "published_display": "26 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex Life Sciences Corp. (AVXL) Stock Analysis: Exploring The 547% Potential Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNbjNRWVBlcmVyWDNWck43aWJkT1VKUGRCSHd2eV9vSENGTnZmcDhiVFVDRDRJM1RHV2lGaHdWTXlab1J3ZTdnaVhVeXNyRHhPMklvQW1lN1pzczV1SGVRd0xYNEZLZXRvWFJqY3VNekgtN1QwUEROdHBsek1uVm8xVHh5d2JNdW1vYXZ5VkR2eTh1NFZzbVFKY2dpc05zRDNwSnRiNnhmcEduSkhVZ3NJUXBoYkxHb2NOODZqbVJMWGtuRVlaWUk1bTh1MA?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex CEO Christopher Missling speaks April 14 at Needham", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPOGcteE9ndmJBQVFZSDFOUFRWeHExU1Y0bVpJV2NydzRHUFVpaTJ0RkRHV0V6cURJMjlIS25mQ1F5OEpUcEppLVBlaldRcW5iZGx0SDBDWHBYRm03dFFoU3ItWjdDREVvZHhqc0FQUThIZUVVM1VOb0RvT29pbHVBQXFmNWtRNTZrRGNYTWE4WWlrQWZtcEppWTNZSjNpclowNmZVemR6WmNaLVh4YVU2Zlg5SE1oNmx3SnM3M3dn?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex Life Sciences Corp. (AVXL) Stock Analysis: Exploring a Potential 635% Upside in Biotechnology", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxPMERVRnVOY1JzQ3hHX2VRT05VRDh1ODZfU3RMOXhuOWwwR1M0WC0tenQxREljMjZSOWZ5SEVsQVY3TTVNMEN5cXEzTjNuLXBwRVF4bFMxbEQ4WVBCN3dUSTc0UmRhTUdtSmlQZnhCZlVfLU9yVEFjQjlYc0RTaUFvM3VjTU53QTh5Rk9HSFFiYjNmdVZVc1g5Y0J0d21GVzhyX05GMVRLR19wYk9uTGZMYzEzaEhyTUtUZGZYMy0yaXhiQ2F1MkEtaGYwbzZXMGtKdGRCazJQdzhsbC1TcWxZ?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-04-03T07:00:00+00:00", "published_display": "03 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After withdrawing its EU filing, Anavex keeps Alzheimer\u2019s drug in talks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNVlNNc28zTmxSd3JnQXZGTUtrS0lrRTliZkRtQ3prbmk0MUNFOTIxQmYyeEFydWxxMzYwcEVsdkJRQ3dCTEZQSFRkeDBqOUgxVENfTkJkdUJCc0ZnRVppTENScE9VWHI3VTNtcUc4QkxMaTVzbkptV083bC1HZXlQbjhmaUloRUFpLVpISDRpNUpOSllLdWg2eWhpZW5MeEJ0NnNHNl9YWHItajh2aVE?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex Life Sciences Stock Is Deeply Oversold. Should You Buy the Dip?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNTWI2Q3FPazVRbkRULXJaa2pXNlpzcEE5VV8tbUVlbkJOYkZRZUVQa0VJbWZqZTZuUmJKdnYzSk5wQnh5RnVRSmlRcElGNGtsZ19zN2ZVR3duRnJ3cjd4SnVfTmRXckluYS00VnZxbmdwdGdid1NUODJPbXdsd0dydFhFMWVZcUFmWkpLZHVSLU44Tkl5OENUaVZ3U212Z1U?oc=5", "source_name": "Market source", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxPQXpoZERCMDl6d3pQR2RZMjBlM180bENuVHdfRHNNZWdVMUljSUJfM3ZKMEFFTXF4S1YtWkQ2cXRHakN1UXRVNms5R0MwcG5zWEd2LTVCc1N0LWVMUXFiWFhfc085b3ZKZGNmTk5jOHlsXzZvYW5paHU3ZDd0dVU5MVRGMVR2OUhORWZfNjEyZm4?oc=5", "source_name": "Market source", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AVXL Stock Tanks After Anavex Withdraws EU Bid For Alzheimer's Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNYzF0OUtRRU9WaWR3d3FXZS0zVGZGTDhTRHphak10ZUFFM2lzel91M1czN2M4X0VwbFlndWxidXN0b05fOFNmZGxPT0R0UWE2YzdzU2lzVXE2RW02eGZMRGxZbjk5TzlJdVpTRzdhOUdCV3VPdDRYX0hFR3MwVlIyVzRPbVVlb2g4aU1FclZSZ3UyZERERzc5bzNRYkpwMmI3RlB2Z3g5UWh4cklhMnpUWkxKMG9zRG9IcXd0S3VwVF85cVAwbTZUdQ?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EU review halts Anavex\u2019s Alzheimer\u2019s drug bid, more data next", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOM05XTEZ5SUdybTk1MUp2eXZlX21CY2xUOEpGRVhJblNjN3NPdlZHZFFaWXBZdTFmV1MyNVlDUER3VklKSExpR0w1VEN4NkNDTGNtclFzNHNqN1JPN0M4bHQ3NWVjRHlaQ0RTeURZMU44ZmU3ckJ2eTF2WmtHMjhzYzNRVEhvUnhiSXFkQ0d0Vlk4SEpfTGc3d2wzSzJWY1NTeTBRaV9kaDJHQ3dEU0pueWFGOXk0RW1HYm9rV2Fxaw?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AVXL Stock Soars After Anavex\u2019s New Data Suggests Its Alzheimer\u2019s Drug May Slow Brain Shrinkage", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxNdTNrODBQd21DX3lDVjJXeXdWYmJpeG1FZ0ZLS3YxbWs4OUlfazZtZ3lwcm0xS3UwbVBVdzBxQVpNWWt1XzluZ1ZDcW9aNTByNjQwbS1XckRnYjB5ZWU4bmdaNXBXVk5lcWwwS3VpQWVhb3hlN0tDOHVBT01aN3NZV01ya25peDRMT0Uyc25hU3NxbkViamlwQXU3VXRmZlJBc1ZlZXFGaENTSmx5MFVGOGJHTzBUdHZ0ODBHWDBLSEdJcU5aZmVrUFQyUjRDWVpFdnVoTg?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex Life Sciences Stock Rises After Experimental Alzheimer\u2019s Drug Slows Cognitive Decline In Study", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxPVEQxZVJCaFp2NVJOTWF6N0gtam9Ha01uRThjNkhpeEtaTTZ2ZnBXYlFDYlJSLVRvS012NWxkUEd0MWZlVVo4ZlNQVDhycTAzdFoxMzhrV1lBM3o1SXFmczhfSEEtenk2WXZ1bnhORGlyLWFQUnpQdF94bUlVcUpQRlZNbjkzQ082QTBTNExEUl9uWlBLeGVidlI4Q1dEbzN1RndWRzhfbTNHT2UtVlEwS0NDT21yNDRHcUpTY2MySVR4NFJNWHB2WV9iT1BJeWp0Qk0ta0F5VFpRVVJDRUloeUUzekFLMm9nTUpZ?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex Life Sciences (AVXL) Upgraded to Buy: Here's What You Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxONmVOdXVCVEtTZ01LUEY0b0lCMGZLWDhvby05TWFPTkViSVRSSjVXbzdDa3c4Um5qRXZiS1VkSEx5dFRFNGZHVjhQWXZSaWRyVVlTMTlsU25IUnNROENSajRwSWZERDc1UmxPSnZ1TVZTUnYwMEY5T1dackRWV1pxSG1LYmZCOWs?oc=5", "source_name": "Market source", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Anavex Life Sciences (AVXL) Stock Outpacing Its Medical Peers This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxPSW43b2tQQ2lzdGtSeUdkbnNwcWtZLXdqSEpVOUxONTRXYjBuTzJxMV9uUFR4ZWdRcXZfWk9vX2VMNmZNejZhR2FxajBTZTUwZ2x0OFk0ZU9EYk5RZ19mazhNNkQ3SkNaOUFqWjJkLUhxUzZnM2lLNm80Rm93ZThwai1Obw?oc=5", "source_name": "Market source", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex Life Sciences Corp. Common Stock (AVXL) Stock Price Today: $2.43", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE1wakkxRmRmSzNfTWpfQ0NUdExIQXY5TVJPME5MZmRJT2lUSk4weTRoUEpHeHJic2E3aFFvMGZtUmZkRnlGazRUaVBhMHlGTUVfRUhDalBwWQ?oc=5", "source_name": "Gotrade", "published_at": "2026-02-02T07:11:00+00:00", "published_display": "02 Feb 2026 07:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Down 50.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Anavex Life Sciences (AVXL)", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTFAwUzNGOG1XWm05LW9ZbDJ1MV9MUUg5YlV1WGFCOWRpQmFqNmZpbTJ2eFNROVpzY3pjcTFBU1RLSml3NUhEeVc5QWM2Vy10RERDS1ZyZi05QTM0X1JacnZsZU1CSjB6eURoZW1jNWZQU0g?oc=5", "source_name": "Market source", "published_at": "2025-12-02T08:00:00+00:00", "published_display": "02 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPdkZmb1BmZWU1WUY3UFh4QkNFdzMxc19LWEhpMzdWZlh5eWJjTDJGcmF2SS0wVnV0ZlVRMmRTSUdhaDlDR0ZEY3BRY1AwYkV5TU1QVVJXalpzeFlVVTdteXk2YWdaMVJqU0J0YkxXOGRrSmlKdWlOV3gxQlFtM0M0QUp6UjRQcGxrcTRia2J5bFB5RHczNnktNTVkblhwYWhHZFdBbWZWQTVkXzhSZVh0VGFkdWtDTFBfbHNQUlFaRXZjTlByQWc?oc=5", "source_name": "Anavex Life Sciences", "published_at": "2025-11-25T08:00:00+00:00", "published_display": "25 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Anavex Life Sciences (AVXL) Is Down After an EMA Setback for Its Alzheimer\u2019s Drug Application", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-16T08:00:00+00:00", "published_display": "16 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AVXL Stock Price and Chart \u2014 NASDAQ:AVXL", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE50N29nWllNbmlzNmFmZHItd3VJZkNYZjZZaWljR1lRTzFReHV3WWl4OGQ1U3RsLXpNbTlhVTJ6bUpEVDFkWjd5dG9vQ0F0WllpYlM4aDRVWXg0ZHhC?oc=5", "source_name": "TradingView", "published_at": "2025-10-29T07:00:00+00:00", "published_display": "29 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anavex Life Sciences Stock Falls After Hours On $300M Raise Plan; Retail Traders Think It\u2019s A \u2018Smart\u2019 Move", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-wFBVV95cUxPejlmR0ViX1VNSmd1V2w0a1RvZm5CYUpKYUFrYmRHS1ZBNHc4RktvWURrdzlQZTQwd0daWUZpRHpsclpreURhYV8zNjJtRk9taTNWOFFiUkMzb1htdHpzYzZTb1hFc2NxY3g2RWRCMXJMZjJlaW5Xak9EdEwxTHh5dTdWTm5QaDZ5SkRhTVR5NTZvSHdvZDhSdWw2R1kzOGFKRE5nYW9qYmM2cUhhR1JiUWtTM0hGUm9QaUppN3FDVngyTGEyaHFqMG00OFN4NkNWZGNEWWhoOGVQVU9maWRPendWZjNFNEdKUXBaNG1NYmNLWnFObkpHR3lGVQ?oc=5", "source_name": "Stocktwits", "published_at": "2025-07-14T07:00:00+00:00", "published_display": "14 Jul 2025 07:00", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 99, "total_relevant": 61, "sentiment_summary": {"positive": 8, "negative": 16, "neutral": 37, "score": 46, "total": 61, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 19.6, "count": 35}, {"event": "earnings", "label": "Earnings", "weight": 9.76, "count": 20}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 8, "negative_events": 16}, "market_context": {"has_market_context": true, "latest_close": 2.39, "latest_week": "2026-07-17", "one_week_move": -4.4, "four_week_move": -12.5, "twelve_week_move": -28.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.417603, "market_dynamics_buy_signal": false, "relative_strength": -61.274028, "fair_value_gap": -63.3, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 43.945, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-4.4% over one week, -12.5% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 63, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 13}, {"label": "TradingView", "count": 11}, {"label": "Stock Titan", "count": 9}, {"label": "Stocktwits", "count": 4}, {"label": "simplywall.st", "count": 3}, {"label": "TradingKey", "count": 2}, {"label": "Moomoo", "count": 2}, {"label": "The Globe and Mail", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 52}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 35}, {"label": "Earnings", "count": 20}, {"label": "Analyst action", "count": 3}, {"label": "Regulatory and legal", "count": 1}, {"label": "Guidance", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "46/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "52", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-4.4% over one week, -12.5% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Anavex Life Sciences Submits Plan to Regain Compliance With Nasdaq Timely  Filing Rule"}], "updated_at": "2026-07-21T02:53:14.930908+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}